These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 24485799

  • 1. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S, Sankar R, Varunkumar K, Ravikumar V.
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S.
    Clin Cancer Res; 2008 Jan 15; 14(2):549-58. PubMed ID: 18223231
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 8. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
    Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA.
    Clin Cancer Res; 2010 Jan 15; 16(2):554-65. PubMed ID: 20068080
    [Abstract] [Full Text] [Related]

  • 9. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
    Sato A, Asano T, Ito K, Asano T.
    Urology; 2012 Apr 15; 79(4):966.e13-21. PubMed ID: 22296623
    [Abstract] [Full Text] [Related]

  • 10. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
    Bao L, Diao H, Dong N, Su X, Wang B, Mo Q, Yu H, Wang X, Chen C.
    Cell Biol Toxicol; 2016 Dec 15; 32(6):469-482. PubMed ID: 27423454
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
    Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR.
    J Thorac Cardiovasc Surg; 2004 Apr 15; 127(4):1078-86. PubMed ID: 15052205
    [Abstract] [Full Text] [Related]

  • 13. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    Sato A, Asano T, Ito K, Sumitomo M, Asano T.
    BJU Int; 2012 Apr 15; 109(8):1258-68. PubMed ID: 21895936
    [Abstract] [Full Text] [Related]

  • 14. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.
    Imesch P, Fink D, Fedier A.
    Fertil Steril; 2010 Dec 15; 94(7):2838-42. PubMed ID: 20605144
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
    Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T.
    Anticancer Res; 2006 Dec 15; 26(3A):1869-76. PubMed ID: 16827119
    [Abstract] [Full Text] [Related]

  • 17. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
    Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM.
    Epigenomics; 2012 Oct 15; 4(5):571-89. PubMed ID: 23130838
    [Abstract] [Full Text] [Related]

  • 20. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P, Junghanns C, Mandl-Weber S, Strobl S, Oduncu F, Schmidmaier R.
    Br J Haematol; 2012 Mar 15; 156(5):633-42. PubMed ID: 22211565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.